Omada Health (OMDA) reported Q4 2025 revenue of $76 million; net income was $5 million and adjusted EBITDA was $8 million. Gross margin in Q4 was 71 percent and non-GAAP gross margin was 73 percent. For the full year (FY) 2025, OMDA reported revenue of USD 260 million (up 53 percent), a net loss of USD 13 million and adjusted EBITDA of USD 6 million. FY gross margin was 66 percent, non-GAAP gross margin was 68 percent; cash and cash equivalents amounted to USD 222 million. Membership at year-end was 886,000 (up 55 percent). Operationally, OMDA highlighted GLP-1 activities (more than 150,000 members supported on GLP-1s) and announced GLP-1 Flex Care; it also launched AI tools OmadaSpark and Meal Map in 2025 and announced Omada for Cholesterol in February 2026. CEO Sean Duffy highlighted growth, profitability milestones and progress on GLP-1 support, AI capabilities and program enhancements. Outlook: For FY 2026, OMDA expects revenue of $312 million to $322 million and adjusted EBITDA of $7 million to $15 million.
Source: Reuters.com
